From gene editing to microfluidics, the scope for innovation in the field of life sciences is vast and ever-expanding. Yet many researchers don’t know how to make the leap from academia to industry.
Concordia’s District 3 aims to do something about that.
The District 3 Innovation Centre is working with the City of Montreal to help the biosciences and life sciences industries address shortages of scientific talent, as well as to train graduates who seek jobs to match their skill set.
“I’m thrilled to be joining Deloitte and continue to follow my passion for understanding how data science methods and technologies can be applied to biomedical data to yield a better understanding of biology,” Bonazzi said. “I’m looking forward to supporting agencies in their mission to utilize data science to better understand and use complex biomedical data.”
Plans are moving forward for another Bay Area biotech campus. Alexandria Real Estate Equities is transforming a chunk of property in San Carlos into a 1.6 million-square-foot biotech campus.
According to the San Francisco Business Times, the real estate development company submitted plans for its proposed biotech campus. The site in question includes multiple office buildings, including the former corporate headquarters of Kelly-Moore Paints. Most of the buildings on the swath of property are decades old. Alexandria Real Estate Equities intends to turn the space into six new buildings, each about five to seven floors for biotech companies to use. In addition to the buildings, the site will also include an amenities structure, parking garages and a small park, according to the Business Times.
CAMBRIDGE, Mass. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation® technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.
ROCKVILLE, Md., Nov. 25, 2019 /PRNewswire/ — Emmes today announced that Lynn Lewis has joined the company as chief business officer, a newly created position. Her overall focus is to build deeper relationships with existing clients and to develop new business opportunities, particularly among biotech and pharmaceutical companies.
Lewis will be responsible for sales, marketing, communications, strategic planning and partnerships, and proposal development.
Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “Lynn understands the importance of science in our business. She will extend our reputation and value as a trusted scientific partner with those who share our passion for designing and executing important studies aimed at improving human health.”
Recorded at the BioHealth Capital Region Investor Forum: Christian Barrow, Executive Director of Life Sciences Banking with JPMorgan Chase, guests on BioTalk to talk about his background working with life science companies, healthcare Investing, and the BioHealth Capital Region.
Listen now on Apple Podcasts https://apple.co/35zhnxI, Google Podcasts http://bit.ly/34kY1MP, and TuneIn http://bit.ly/2QQScTs
Chris Barrow is a senior banker with J. P. Morgan commercial bank. Chris joined J.P. Morgan in 2012 in the Philadelphia office, where he and his team focus on providing financial solutions to life sciences companies located in the Mid-Atlantic – Delaware, Pennsylvania and Maryland. Chris has over 25 years of experience in the financial services industry with roles that have spanned from public accounting to banking.
Chris’ current job is to help life science companies – biotech, specialty pharmaceutical, specialty pharmacy, medical device, med-tech, medical diagnostics and contract research organizations – gain access to JPMorgan’s well-known healthcare commercial and investment banking resources.
Prior to his current role, Chris started his career with EY (inactive CA and CPA licenses). He subsequently served as a senior banker for Bank of America. In this capacity, he was responsible for origination and structuring of debt products to general industry companies located in Pennsylvania.
Chris holds a bachelor’s degree in Biology and a graduate diploma in Accounting both from McGill University. He currently resides in Doylestown, Pennsylvania with his wife and two children.
Recorded at the BioHealth Capital Region Investor Forum: Christian Barrow, Executive Director of Life Sciences Banking with JPMorgan Chase, guests on BioTalk to talk about his background working with life science companies, healthcare Investing, and the BioHealth Capital Region.
Listen now on Apple Podcasts https://apple.co/35zhnxI, Google Podcasts http://bit.ly/34kY1MP, and TuneIn http://bit.ly/2QQScTs
Chris Barrow is a senior banker with J. P. Morgan commercial bank. Chris joined J.P. Morgan in 2012 in the Philadelphia office, where he and his team focus on providing financial solutions to life sciences companies located in the Mid-Atlantic – Delaware, Pennsylvania and Maryland. Chris has over 25 years of experience in the financial services industry with roles that have spanned from public accounting to banking.
Chris’ current job is to help life science companies – biotech, specialty pharmaceutical, specialty pharmacy, medical device, med-tech, medical diagnostics and contract research organizations – gain access to JPMorgan’s well-known healthcare commercial and investment banking resources.
Prior to his current role, Chris started his career with EY (inactive CA and CPA licenses). He subsequently served as a senior banker for Bank of America. In this capacity, he was responsible for origination and structuring of debt products to general industry companies located in Pennsylvania.
Chris holds a bachelor’s degree in Biology and a graduate diploma in Accounting both from McGill University. He currently resides in Doylestown, Pennsylvania with his wife and two children.
Usually BioHealth Founder and CEO, Rich Bendis, is the host asking questions of his guests on the BioTalk Podcast. However, Rich was recently a guest on the “The ZIDDANDFIXX Show: Angels Talk” Podcast for their 26th Episode titled “The Golden Triangle: DC joins San Francisco and Boston.” They discussed Venture Capital, Angel Investment, and the BioHealth Capital Region.
Ziad Moukheiber of Boston Harbor Angels (East Coast), and Faz Bashi (West Coast) of Life Science Angels have a good time chatting about Angel Investing, Entrepreneurship, Restaurants, Politics with good friends and always with great humor and lots of laughter!
Listen now!
Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the world’s burden of AMR and in 2017, there were more than half a million cases of DR-TB globally – including some right here in the District of Columbia. It is estimated that two-thirds of individuals with DR-TB do not even know they are infected, posing a threat to their own health and to global health security.
One company gets absorbed into a larger brand and a host of companies flower as a result. The Biohealth Capital Region’s (BHCR) cycle of creative destruction has continued with Harpoon Medical. This was the story shared at the TEDCO Entrepreneur Expo’s session titled, “Success Breeds Success.”
Image: https://biobuzz.io
